Analyst Update: Five Below, Inc., Dillard's, Inc., and Atara Biotherapeutics, Inc.

Analysts adjusted their ratings on Five Below Inc (NASDAQ:FIVE), Dillard's, Inc. (NYSE:DDS), and Atara Biotherapeutics Inc (NASDAQ:ATRA)

by Karee Venema

Published on Jun 4, 2015 at 1:33 PM

Analysts are weighing in on retailers Five Below Inc (NASDAQ:FIVE) and Dillard's, Inc. (NYSE:DDS), as well as drugmaker Atara Biotherapeutics Inc (NASDAQ:ATRA). Here's a quick roundup of today's brokerage notes on FIVE, DDS, and ATRA.

  • FIVE is popping today -- up 8.2% at $37.98 -- after the firm's better-than-expected first-quarter results and upwardly revised full-year forecast received a round of applause from the brokerage bunch. Dougherty, for example, raised its price target by $5 to $45, while Barclays boosted its target price to $44 from $42. Wells Fargo, meanwhile, said Five Below Inc's "growth story is back on track," and should continue to improve. Since late April, FIVE has been sandwiched between support at its 60-day moving average and resistance at its 32-day trendline, but thanks to today's gap, the security is on pace to close north of its 320-day moving average for the first time since Jan. 8. Meanwhile, it appears option traders were betting on a post-earnings slide. The stock's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.64 ranks in the 90th annual percentile, meaning puts have been bought to open over calls at a near-annual-high clip.
  • Credit Suisse weighed in on department stores today, downgrading the sector as a whole to "underweight" from "market weight." The brokerage firm also took aim at individual names within the sector, and for DDS, this resulted in a rating cut to "underperform" from "neutral." In response, the shares have tumbled 2.4% to $114.40, and are at risk of closing south of their 320-day moving average for the first time since February 2014. Longer term, Dillard's, Inc. has surrendered nearly 21% since topping out at a record high of $144.21 in mid-April, but option traders have been rolling the dice on a bounce. At the ISE, CBOE, and PHLX, the security's 10-day call/put volume ratio of 1.16 rests higher than 66% of similar readings taken in the past year.
  • Biotechs have been garnering a lot of attention this week, and sector component ATRA saw its price target lifted to $47 from $43 at Jefferies overnight -- sending the stock 4.7% higher today to $42.83. This positive price action is just more of the same for an equity that's surged more than 60% year-to-date. Should Atara Biotherapeutics Inc extend this momentum, another round of price-target hikes could be on the horizon, considering the stock's consensus 12-month price target of $42.67 is roughly in line with current trading levels.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

Look Who's Going Bankrupt Next in America
Porter Stansberry is making a concerning prediction.
First Week in April Provides More Coronavirus-Related Volatility
A slew of coronavirus-related news sent markets on another weekly roller coaster ride
Netflix Stock Heading into Historically Bullish Quarter
NFLX's 10-day moving average has stepped up as support lately
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.